Chronic kidney disease

By A. Levey, Josef Coresh. The Lancet, 2012

6,497 citations recorded by the source corpus.

Subfields: Hematology, Nephrology

View Paper: https://www.semanticscholar.org/paper/55e7b66ab73be8df984832f0162b2db5c5b0046a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. W. Herrington
2. Zahed Siddique
3. Minyang Fu
4. B. Lacey
5. M. Ahsan
6. P. Sherliker
7. C. Ndumele
8. J. Armitage

Citations in the corpus

• The Hippo signalling pathway and its implications in human health and diseases (2022, background): “Diabetic and polycystic kidney diseases are two types of chronic kidney diseases.(15,313) They are all related to dysregulation of the Hippo pathway.”
• Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association (2023, background): “47 Even when CKD occurs from other causes, in the absence of hypertension and diabetes, the impact on CVD risk and the therapeutic approaches to prevent kidney function decline are largely similar.”
• Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia (2014, background): “Standard medical treatment and follow-up of CKD follows the established general therapeutic principles of patients without an inborn error of metabolism [258] including control of blood pressure, electrolytes, secondary hyperparathyroidism, and renal anemia and associated osteodystrophy.”
• Machine-Learning-Based Disease Diagnosis: A Comprehensive Review (2021, background): “The recent advancement of ML and DL-based kidney disease diagnosis may provide a possibility for those countries that are unable to handle the kidney disease diagnostic related tests [49].”
• Trends in insulin resistance: insights into mechanisms and therapeutic strategy (2022, background): “Identifying new therapies to reduce IR may contribute to the reduced prevalence of CVDs. Alzheimer’s disease and IR Alzheimer’s disease (AD) is a progressive neurodegenerative disease and is considered the sixth leading cause of death in the United States, with most patients aged 65 or older.367 Rec”
• Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. (2016, background): “Kidney Disease and Atherosclerosis Reduced glomerular filtration rate defines CKD and is identified in at least 5% of the US population.(98) More severe CKD (ie, lower glomerular filtration rate) is associated with increased vascular risk: compared with those with normal renal function, an estimated”